Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLDL1278A in stable atherosclerotic cardiovascular disease
NCT01258907Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2010
- Primary completion
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of orticumab in atherosclerosis (3 arms), sponsored by Genentech. Primary endpoint: Target-to-Background Ratio at 12 weeks. Started Mar 2010; status: completed.
02
Drugs
orticumab
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT01258907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01258907.